Tag Archives: Elan

Voting for ‘None of the Above’ At Elan

The latest development at Elan is that the Company went to court to block Royalty Pharma‘s buyout bid, which says something about their confidence that they can make the case to their own shareholders. The shareholders deserve something better than … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment

Elan: If You Can’t Beat Them, Be Them

Freud (Anna, not her father) coined the psychoanalytic term ‘identification with the aggressor’ to describe a process wherein an individual identifies with–and emulates–the behavior of someone they experience as a threat, in order to feel less vulnerable. Elan has now … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , , | Leave a comment

Clarity Elan Style

The announcement that Elan has sold its Tysabri part-ownership to Biogen-Idec raises some interesting questions about Elan’s direction.  What better way to assess their strategy than by their own words? June 3, 2010 (Elan PR, from their Chairman) “Mr. Martin … Continue reading

Posted in Big Pharma, Uncategorized | Tagged , , | Leave a comment

Elan Corporation: 1969-2013

Elan has announced that it will spin off Neotope Biosciences as a repository of all its preclinical/discovery research–devoted to targeting rogue proteins (amyloid, tau, synuclein) in the treatment of neurodegeneration. Elan’s longterm CSO, Dale Schenk, is the CEO; Elan intends … Continue reading

Posted in Uncategorized | Tagged , , , , | 1 Comment

Putting Bapi in Perspective

The topline results of the first bapineuzumab Phase III to report came out today, and to the surprise of no one that we know, they were negative. This trial was in APOE4 carriers, the next Phase III trial to report  … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , , , , | 1 Comment